Phenylpiracetam Carphedon Tablets

Description Phenylpiracetam Carphedon CAS Number 77472-70-9 Molar Mass 218.256 g/mol Chemical Formula C12H14N2O2 IUPAC Name (R,S)-2-(2-oxo-4-phenylpyrrolidin-1-yl)acetamide Introduction Phenylpiracetam Carphedon Tablets are novel research compounds designed for scientific investigations, specifically in the fields of weight loss, cognitive enhancement, and physical energy. It is crucial to underscore that these tablets are strictly intended for research purposes, and any suggestion of human consumption is prohibited. Key Characteristics Phenylpiracetam Carphedon is a nootropic compound, known for its potential cognitive benefits. Phenylpiracetam is a derivative of piracetam and exhibits unique pharmacological properties, making them a subject of interest in various scientific studies. Research Applications Researchers explore the diverse applications of Phenylpiracetam Carphedon Tablets in neuroscience, metabolism, and energy-related studies. The compound’s potential effects on weight loss, cognitive function, and physical energy make it a versatile tool in laboratory investigations. Research Benefits Phenylpiracetam Carphedon and Weight Loss Studies suggest a potential link between Phenylpiracetam Carphedon and weight loss. Research investigates its influence on metabolic processes, appetite regulation, and related mechanisms to better understand its impact on body weight. Phenylpiracetam Carphedon and the Brain Phenylpiracetam Carphedon’s cognitive-enhancing properties are a focal point in neuroscience research. Investigations explore its effects on memory, learning, and overall cognitive function, shedding light on its potential applications in cognitive research. Phenylpiracetam Carphedon and Physical Energy The compound’s impact on physical energy is of interest in studies related to fatigue and physical performance. Researchers aim to explore the mechanisms through which Phenylpiracetam Carphedon may influence energy levels. Summary Phenylpiracetam Carphedon Tablets offer potential benefits in weight loss, cognitive enhancement, and physical energy research. As a research tool, these tablets contribute to our understanding of the compound’s effects on metabolism, cognition, and energy-related processes. Disclaimer This content is presented exclusively for educational purposes and should not be construed as medical advice. THE MATERIALS REFERENCED HEREIN ARE EXCLUSIVELY INTENDED FOR LABORATORY AND RESEARCH USE. Any clinical research initiatives must be conducted under the guidance of the relevant Institutional Review Board (IRB). Similarly, preclinical research involving animals must comply with the directives of the Institutional Animal Care and Use Committee (IACUC), adhering to the standards delineated by the Animal Welfare Act (AWA). Our informational content is meticulously designed for research-oriented insights and is not a substitute for individual analysis and verification from credible sources before any purchasing decisions are made. Upon the finalization of your order and payment, you explicitly acknowledge and agree to adhere to our Terms and Conditions. Customer contentment stands as our paramount concern. Should you find any dissatisfaction with the product received, kindly contact us at 419-707-5450 or email our support team at [email protected]. IMPORTANT NOTICE: All products showcased on our platform are EXCLUSIVELY INTENDED FOR LABORATORY AND RESEARCH APPLICATIONS. They are expressly not intended for veterinary or human utilization. References Zvejniece L, Svalbe B, Vavers E, Makrecka-Kuka M, Makarova E, Liepins V, Kalvinsh I, Liepinsh E, Dambrova M. S-phenylpiracetam, a selective DAT inhibitor, reduces body weight gain without influencing locomotor activity. Pharmacol Biochem Behav. 2017 Sep;160:21-29. doi: 10.1016/j.pbb.2017.07.009. Epub 2017 Jul 22. PMID: 28743458. [Read More]. Tiurenkov IN, Bagmetov MN, Epishina VV. [Comparative evaluation of the neuroprotective activity of phenotropil and piracetam in laboratory animals with experimental cerebral ischemia]. Eksp Klin Farmakol. 2007 Mar-Apr;70(2):24-9. Russian. PMID: 17523446. [Read More]. Vasil’eva EV, Salimov RM, Kovalev GI. [Effects of nootropic drugs on behavior of BALB/c and C57BL/6 mice in the exploratory cross-maze test]. Eksperimental’naia i Klinicheskaia Farmakologiia. 2012 ;75(7):3-7. PMID: 23025044. [Read More].